Colonization of the upper respiratory tract with Streptococcus pneumoniae is the precursor of pneumococcal pneumonia and invasive disease. Following exposure, however, it is unclear which human immune mechanisms determine whether a pathogen will colonize. We used a human challenge model to investigate host-pathogen interactions in the first hours and days following intranasal exposure to Streptococcus pneumoniae. Using a novel home sampling method, we measured early immune responses and bacterial density dynamics in the nose and saliva after pneumococcal exposure. We found that nasal colonization can take up to 24 hours to become established. Also, two distinct bacterial clearance profiles were associated with protection: nasal clearers with immediate clearance of bacteria in the nose by the activity of pre-existent mucosal neutrophils and saliva clearers with detectable pneumococcus in saliva at one-hour post challenge and delayed clearance mediated by an inflammatory response and increased neutrophil activity 24 hours post bacterial encounter.
50% of individuals are identified as carriers, but the early kinetics of bacterial clearance or colonization onset have not been assessed. Here, healthy adult volunteers were challenged with S. pneumoniae, after which they self-collected saliva and nasal lining fluid (nasosorption) samples for bacterial kinetics and immune monitoring in the first 48 hours. We compared non-colonized and colonized subjects to identify potential correlates of protection and to define the kinetics of colonization. Our hypothesis was that mucosal innate responses would be predictive of protection against colonization and the movement of bacteria from the nose (site of exposure) to the saliva within the first 48 hours would be associated with less effective immunity and potentially with colonization.
Results

Home sampling method can be used to collect samples at defined timepoints
Forty volunteers aged 18-32 years were screened for pre-existing colonization with pneumococcus and non-colonized participants were inoculated with 6B pneumococcus, as previously described 16 . Colonization status was defined by classical microbiology culture of S. pneumoniae serotype 6B in nasal wash samples collected at day 2, 6, 9 and 14 post exposure.
Volunteers with negative samples at all time points were defined as culture-negative and those with a positive sample at any time point were classified as culture-positive. Following exposure, 30 volunteers remained culture-negative (75%) and 10 became culture-positive (25%) ( Table S1 ). Colonization status was confirmed by lytA qPCR in nasal wash.
Saliva and nasal lining fluid samples were obtained before exposure (Time=0 hours, baseline).
Volunteers collected their own saliva into pre-prepared tubes at 1, 2, 4, 8, 12, 24, 36, and 48 hours, and anterior nasal lining fluid (by nasosorption strip) 17 at 24 and 48 hours. A subgroup of 33 volunteers self-collected additional nasal lining fluid samples at 4 and 8 hours ( Figure   1A ). To monitor compliance, volunteers were instructed to record sample collection times using their mobile phones, sending pictures of the collected sample to the research team at the time of sample collection. Samples from two volunteers were excluded (5%) due to poor compliance detected by temperature monitoring (half of their samples were stored at room temperature, Figure S1A ). Therefore, data from 38 volunteers were evaluated in this study ( Figure S1B ); 29 culture-negative and 9 culture-positive volunteers (Table S1 ). This high rate of compliance indicates the successful application of our novel sampling method.
Raw and culture-enriched DNA extraction in saliva are complementary for Spn detection in saliva
To detect Spn presence, pneumococcal genomic DNA was extracted from both raw and culture-enriched (blood agar plate with gentamicin) saliva samples, as the later has been shown to be the best method for pneumococcal detection in saliva 18 . In total, 58 Spn hits were detected using a Spn 6A/B capsule-specific qPCR (26 in raw samples, 16 in cultureenriched, and 16 in both, Figure S1C ). Spn density from culture-enriched samples was significantly higher (lower Ct values) than from raw samples ( Figure S1D ). Consequently, samples with a positive result using either method were included in further analyses.
Two distinct profiles of bacterial clearance kinetics associate with protection against colonization
To investigate Spn clearance kinetics, we assessed the presence of pneumococcus DNA in saliva in the first 48 hours after exposure by qPCR ( Figure 1A) . At one hour, amongst culturenegative volunteers, Spn DNA was detected in the saliva of 12/29 (41.4%) volunteers (Figures 1B and 1C) . This suggests that two distinct profiles of protection against colonization exist.
We named these two groups "nasal clearers" (individuals with no detectable Spn DNA in 1hour post-exposure saliva samples) and "saliva clearers" (individuals with detectable Spn DNA in 1-hour post-exposure saliva samples). Nasal clearers showed similar levels of Spn density between 2 and 12 hours ( Figure 1D ). Saliva clearers showed a peak of Spn density (DNA copies/ml saliva) at 1 hour after exposure and followed by gradually decrease of Spn density after 1 hour.
Establishment of pneumococcal colonization takes up to 24 hours
Amongst those subsequently culture-positive volunteers, Spn DNA was not detected in any 1hr saliva samples ( Figures 1B and 1C ). At 24 hours, Spn DNA was detected in 6/9 (67%) of culture-positive volunteers, but in only 3/29 (10%) of culture-negative volunteers (Figures 1B and 1C) . Moreover, at 48 hours, Spn DNA was detectable in the saliva of most culture-positive 7/9 (77.8%), but few culture-negative 2/29 (6.9%) volunteers ( Figure 1B ). The mean density started increasing significantly in culture-positive volunteers only from 24 hours. This suggests a gradual colonization process that takes at least 24 hours.
Bacterial DNA detection in the nose
We then evaluated the presence of pneumococcal DNA in the nasal lining fluid during the first 48 hours post exposure by qPCR, as described above ( Figure 1A ). Volunteers missing one or more home samples (n=12; 5 culture-positive and 7 culture-negative volunteers) were excluded from this analysis. At 4 hours post exposure, Spn DNA was detected in the nose of 20/21 (95%) culture-negative, and in all culture-positive 5/5 (100%) volunteers. At 8 hours, Spn DNA was detected in 10/11 (91%) nasal clearers, 6/10 (60%) saliva clearers, and 5/5 (100%) culture-positive volunteers (Figure 2A ). Thus, in 40% of saliva clearers, Spn DNA was completely removed from the exposure site (the nose) within 8 hours. At 24 and 48 hours Spn DNA was detected in nasal lining fluid from only 1/5 culture-positive volunteers, indicating that in 4/5 volunteers the bacteria had either migrated posteriorly, or become attached or internalised at the epithelium. For saliva and nasal clearers, Spn DNA was detected in the nose of 5/10 (50%) and 5/11 (45%) volunteers at 24 hours and 2/10 (20%) and 2/11 (18%) volunteers at 48 hours post exposure respectively. There was no difference in late nasal clearance profile between the two groups ( Figure 2B ).
Pneumococcal agglutination was not associated with early pneumococcal profiles
Agglutination of pneumococcus by polysaccharide 6B (PS6B) specific IgG antibodies has been previously shown to protect against 6B pneumococcus colonization in the context of pneumococcal conjugate vaccination 19 . Also, mucus is known to be able to trap pathogens 20 and to bind pneumococcus through carbohydrate motifs 21 . To investigate whether agglutination correlates with protection or colonization clearance profiles, agglutination capacity was measured in baseline nasal wash samples and compared with the levels of mucin (MUC5AC) and Spn polysaccharide specific IgG antibodies (PS6B) in these samples. Baseline nasal wash agglutination capacity was correlated significantly with high levels of MUC5AC ( Figure S2A and S2B), but not with PS6B-specific IgG levels ( Figure S2C and S2D).The agglutination capacity ( Figure 2C ), MUC5AC, and PS6B-specific IgG levels were not siginficantly different between the three groups in nasal wash at baseline.
Neutrophil activity contributes to protection against establishment of colonization in nasal clearers
Neutrophils are abundantly present in the adult human nose even in the absence of pneumococcal colonization 17 . Neutrophils are activated by bacterial encounter, releasing myeloperoxidase (MPO) during degranulation 22 . To investigate if neutrophil activity at the time of bacterial encounter contributes towards pneumococcal clearance, the abundance of neutrophils and MPO levels were measured at baseline. Nasal immune and epithelial cells were measured from nasal curettes ( Figure S3A) 17, 23 . The absolute number of activated neutrophils were identified by measuring CD66b Hi granulocyte levels, a marker for neutrophil activation 24 . We also analysed total number of granulocytes and the expression levels of CD66b within the granulocyte population based on their MFI (Mean Fluorescence Intensity) ( Figure S3A ).
Nasal clearers showed at baseline 10-fold and 11-fold higher levels of activated (CD66b Hi ) and total granulocytes, respectively, compare to culture-positive ( Figure 3A and Fig S3B) volunteers. Moreover, the granulocytes of nasal clearers had increased expression of CD66b compared to saliva clearers ( Figure S3C ). This finding was supported by increased MPO levels at baseline in nasal wash in nasal clearers compared to culture-positives and saliva clearers ( Figure 3B ). There was a significant correlation between numbers of CD66b Hi granulocytes and MPO levels in nasal wash ( Figure 3C ). There was no significant difference in levels of any other measured cell type (B cells, T cells, epithelial cells and monocytes) between the three groups To assess early neutrophil responses following exposure, we measured levels of MPO in nasal lining fluid in the first 48 hours post exposure ( Figure 3D ). All three groups had comparable levels at baseline. Levels of MPO remained the same during the first two days in nasal clearers and culture-positive volunteers. In saliva clearers, however, levels of MPO rose after exposure and reached a significant peak at 24hours, 3-fold higher than at baseline. Thus, an induced neutrophil response following exposure supports the role of this cell population in protection against delayed colonization in saliva clearers.
A robust inflammatory response is associated with protection from colonization in saliva clearers
To investigate whether a prompt immune response contributes towards protection from colonization by pneumococcus, we measured the abundance of 30 cytokines in nasal fluid using Luminex. A total cytokine induction score was calculated based on all cytokines similar to that previously described for gene expression 25 . Distinct cytokine profiles were observed within the three groups ( Figure 3E ). Culture-positive volunteers had no significant cytokine induction at any time point measured during the first 48 hours, analogous to prior findings at later timepoints 26 . Similar to culture-positive volunteers, nasal clearers showed no significant induction of cytokines at any time point. In contrast, saliva clearers showed a significant induction of cytokines at 24 hours post exposure, with 7 cytokines (IL-6, IL-1β, MIP-1α/CCL3, MIP-1β/CCL4, HGF, TNF-α and IL-8) significantly upregulated ( Figure 3E ). The induction of all of these cytokines except IL-6 strongly correlated at 24 hours with MPO production in nasal lining fluid ( Figure S3H ). These results suggest that saliva clearers induce a strong proinflammatory response, which associates with early neutrophil responses, leading to protection against colonization.
Discussion
To develop effective protective interventions against disease, it is vital to understand which mechanisms play a crucial role in host-pathogen interactions by protecting against establishment of colonization following bacterial encounter. Here we investigated humanpneumococcus interactions in the first 48 hours following controlled intranasal exposure. We tested the hypothesis that volunteers who are susceptible to colonization have a distinct profile of Spn DNA kinetics in the nose and saliva from the culture-negative group.
To our surprise we observed 3 distinct groups: culture-positive volunteers with a high concentration of Spn DNA in the nose 24 hours following nasal exposure, and culture-negative volunteers, among whom there were two groups -one who had detectable Spn DNA in the saliva 1 hour after exposure and another group who did not. We named these two culturenegative groups saliva clearers and nasal clearers, respectively.
Culture-positive volunteers showed no fast initial clearance (appearance in saliva) as well as a lack of cytokine and neutrophil responses during the first hours and days following exposure. Colonization was therefore established in that period. We then observed pneumococcal density diminishing in the anterior nose (exposure site) by 8 hours suggesting that migration towards the nasopharyngeal site may take place by this time point.
Alternatively, the absence of pneumococcus from the anterior nose may reflect strong epithelium binding or even internalization of the bacteria. Indeed, pneumococcus was found to attach to epithelium of the inferior nasal turbinate in the EHPC model during colonization 27 .
Although we see differences these are small numbers. In this group, colonization takes at least 24 hours to be fully established, at which point Spn can be robustly measured in saliva.
Nasal clearers showed a strong baseline neutrophil activation. These volunteers did not develop a significant pro-inflammatory response or had bacterial movement to the saliva within one hour. It is possible that the high level of baseline activated nasal neutrophils prevent sensing by epithelia or other cell types such as monocytes as well as the movement to the saliva. Thus, cytokine responses were not induced in these volunteers. This indicates that neutrophils play a key role in the early control of human pneumococcal colonization. This has not been appreciated in murine models of infections, as neutrophils are present in the nasal lumen of humans 28 , whereas the nasal mucosa of naive mice has no neutrophils 29 and the cell influx occurs only following bacterial challenge. Indeed, the relative prevalence of pneumococcal serotypes in causing colonization in the community associates with their relative capacities to resist neutrophil-mediated killing in vitro 30 .
Saliva clearers demonstrated an initial fast movement of the bacteria to the saliva, which we postulate is due an effective nasal mucociliary activity. In a subset of these (40%), Spn was completely cleared from the nose within 8 hours but it could still be detected in all others at 24 hours. Moreover, saliva clearers induced a strong pro-inflammatory response in the first day post exposure, which we were able to measure at 24 hours. This is associated with a concurrent induction of neutrophil responses. Taken together, this suggests that this group is protected likely by mucociliary clearance which is then supported by a strong neutrophil response to pneumococcus.
Mucus components can influence the bahavior of pathogenic bacteria by increasing their virulence expression, adhesion, motility, proliferation or growth 31 . While bacterial movement suggests that mucociliary clearance could be involved in protection of a subset of volunteers, we were not able to establish a direct link between pneumococcal agglutination and early pneumococcal clearance by mucocilliary movement. The observation that MUC5AC levels correlated with agglutination capacity supports the role for mucus in binding pneumococcus 30 . Neither agglutination nor agglutinating factors (mucus, PS6B), however, associated with early pneumococcal clearance profiles in these unvaccinated volunteers. This result stands in contrast to a previously demonstrated effect of agglutinating polysaccharide specific IgG and its protective role in pneumococcal colonization in the context of vaccination 19 : in this case the levels of polysaccharide antibody are very highly increased at which point mucocilliary clearance facilitated by agglutination may play a role in preventing pneumococcal colonization. The latter indicates that these results might be relevant for vaccine-induced rather than naturally acquired immunity. Alternatively, mucociliary clearance may be important in this defence process. Rapid bacterial migration was protective in the absence of agglutination capacity, nasal ciliary function was not measured in this study.
Smokers 32 and individuals with respiratory tract viral infections, particularly respiratory syncytial viral 33 have decreased mucociliary beating and are more prone to pneumococcal colonization.
Our data describe a novel home sampling method for defining the early events after experimental pneumococcal challenge. Stable colonization following pneumococcal encounter takes at least 24 hours. We demonstrated that there are distinct profiles of pneumococcal colonization kinetics, distinguished by speed of clearance, local phagocytic function, and acute mucosal inflammatory responses which may either recruit or activate neutrophils. These results highlight that when establishing correlates of protection against bacterial colonization, which can be used to inform design and testing of novel vaccine candidates, multiple mechanisms of protection must be considered.
Methods
Experimental Human Pneumococcal Colonization Study -Recruitment of volunteers and ethical statements
Volunteers were enrolled from a concurrent clinical trial conducted in 2016-2017. Details on participant demographics and study's design have been previously described 34 . Limited subject characteristics for this cohort are shown in Table S1 . Briefly, volunteers were screened for S. pneumoniae colonization (natural carriers) and after 6 days were intranasally inoculated with Spn6B serotype (strain BHN418, GenBank ASHP00000000.1) (8x10 4 
Home sampling procedure
Volunteers were given written instruction sheets for sample self-collection and picture taking/sending via mobile messaging application, plus a sample data collection form (time planner). Volunteers were given a transport bag containing 8 x 10mL saliva collection tubes and funnels (plus one spare) (Isoxelix TM , Cell Projects Ltd, Kent, UK) with 1mL skim milk, tryptone, glucose, and glycerine (STGG) media with 50% glycerol for bacterial preservation and transport, 4 adsorptive matrix filter strips (Nasosorption TM , Hunt Developments Ltd, West Sussex, UK) for nasal fluid collection, 2 ice packs for keeping samples cooled during the day, manufacturer's instructions. This method showed same results with the one described previously in this section.
Bacterial DNA extraction from nasal fluid pellet
On the day of the extraction, nasosorption filter strips were thawed for 30min in RT. 100μl of assay diluent added to the filter and centrifuged at 1,503g for 10min. After centrifugation the eluted liquid was moved to a clean Eppendorf tube and centrifuged at 16,000g for 10 minutes at 4 o C. The supernatant was removed and used for cytokine analysis, whereas the pellet was used for DNA extraction. Bacterial genomic DNA was extracted from the nasal fluid pellets using the same method as described above (saliva samples). 
Quantification of pneumococcal DNA by qPCR in saliva and nasal fluid pellet samples
Agglutination assay by flow cytometry
Spn6B cells were grown to mid-log-phase and stored at −80°C in glycerol until use as described before 19 . For agglutination assays with human nasal wash samples, cells were thawed and washed with PBS and 2μl of bacteria was incubated with 48μl of concentrated nasal wash supernatant (1ml of nasal wash concentrated to 50μl using vacuum concentrator and dialysed overnight in PBS using Slide-A-Lyser Dialysis Units (TermoScientific). Antiserum to group 6 (Statens Serum Institute, Neufeld antisera to group 6) was used as a positive control and Anti-Hep-A purified human IgG was used as a negative control (using sepharose and pooled sera from HepA vaccinated volunteers). Samples were vortexed lightly and incubated for 1.5h at 37°C, 5%CO2.
Cells were fixed with paraformaldehyde (PFA) and analysed on a BD LSR II Flow Cytometer (BD Biosciences, San Jose, CA, USA). Bacterial population was gated in the Forward scatter (FSC) and Sideward scatter (SSC) dot plot referring to cell size and granularity. PMT voltages and threshold were gated on negative control bacteria. 30,000 events of each sample were measured by triplicate using FacsDiva Software 6.1 (BD Biosciences, San Jose, CA, USA).
Agglutination was quantified by calculating the proportion of the bacterial population with altered FSC and SSC and values were expressed as % of agglutination, as previously described 35 . All samples were analysed in duplicate and 30,000 events were acquired using FacsDiva Software 6.1 (BD Biosciences, San Jose, CA, USA). Analysis was performed using FlowJo software version 10.0 (Tree Star Inc, San Carlos, CA, USA).
Nasal cells processing and flow cytometry
Cells were dislodged from the curette by repeated pipetting with PBS+ as described previously 17 
Cytokine Analysis
Nasal washes were centrifuged at 1,503g for 10 mins and the extracted supernatant was stored at -80 o C until use. Human MPO was measured according to manufacturer's instructions. The human magnetic 30-plex cytokine kit (ThermoFisher) was used to detect thirty cytokines simultaneously on a LX200 with xPonent3.1 software (Luminex) following manufacturer's instructions. Cytokines for samples with a CV >25% were excluded from further analyses.
Heat map generation and total cytokine score
Heat map representations were generated using R. Fold change concentrations to baseline were calculated for each individual and log2-transformed. An average fold change for each group for each timepoint was then calculated. A total cytokine score was calculated as previously described 35 . In brief, the average log2 fold change of all upregulated cytokines for a given individual was calculated, by replacing downregulated cytokines with a value of 0 and then taking the average cytokine log2 fold change per sample.
Quantification and Statistical analysis
Statistical analysis was performed by GraphPad Prism version 5.0 (California, USA) and R 
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